Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada Calcium is essential for the achievement and maintenance of normal bone health. The current daily requirements for […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada – Updated August 6, 2013 Calcitonin is a hormone found naturally in our bodies. A synthetic form […]

“Patient engagement” is a concept that first appeared around the year 2000 in the United States and is now a growing movement in many countries, including Canada. The core idea […]

Romosozumab EVENITY™ (romosozumab injection) Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.Romosozumab (EVENITY™) significantly and rapidly (over […]

SIGNS AND SYMPTOMS A disease that develops without any symptoms. The First Warning Sign of Osteoporosis is Frequently A Fracture Osteoporosis is a disease that takes years to develop without […]

Osteoporosis Canada continues to advise Canadians to meet the Institute of Medicine established daily calcium requirement of 1000 -1200 mg, from dietary sources preferably, and to use supplements if this […]

ABOUT THE DISEASE What is Osteoporosis? Osteoporosis is a disease that slowly, quietly weakens bones, often going undiagnosed – even when it breaks them. Osteoporosis is caused by low bone […]

The National Osteoporosis Foundation and the American Society for Preventive Cardiology formed an expert panel and completed a detailed review of all published research evaluating the effects of calcium intake […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]